// changes done below on July 01 2024 // till here on July 01 2024

Antibody Drug Conjugates: Contract manufacturing market to evolve rapidly, predicts Roots Analysis

Published: February 2014

Roots Analysis has announced addition of the ADC Contract Manufacturing Market report to their offering. The report provides an extensive study of the contract manufacturing opportunity for this emerging class of therapeutics. It identifies various CMOs active in this space, their capabilities with respect to ADCs, available capacity (clinical/commercial) for bio-conjugation and geographic location/spread of the facilities.

Shivani Singh, the principal analyst, said, “The multi-component aspect of ADCs deems it necessary to have both biologic and high-potency facilities. Despite the fact that this new class of therapeutic agents is gaining increased attention, in-house manufacturing of these molecules is rare.”

“Most of the companies have limited number of ADCs under development. Considering that utilisation rates are likely to be low in near future, the investment required for setting up in-house high-containment biologic facilities is a huge financial risk. As such, majority of the work is currently being outsourced.”

The report examines insights gathered from secondary research and/or interviews of over 100 companies. Examples of companies which were interviewed include:

  • Piramal Healthcare
  • Lonza
  • Catalent
  • BSP Pharmaceuticals

There has been a surge in investments from CMOs for facility expansions during the last one year. Although, there are only three marketed ADCs till date (including Mylotarg), a rich and growing pipeline offers a bigopportunity for contract manufacturers. Roots Analysis predicts that the size of this opportunity is likely to be more than USD 1 billion in near future. The detailed market forecast is based on the analysis of:

  • ADC therapeutics pipeline
  • In-house/contract manufacturing status of phase II, phase III and marketed ADCs
  • Commercial sales potential of molecules under development
  • Likely outsourcing profile across various steps involved in manufacturing

Who will benefit from this report?

This research is targeted towards pharma companies and CMOs working in the field of ADCs. In particular, you could benefit if you are an:

  • Investor
  • Contract manufacturer
  • R&D Manager
  • Business Intelligence / Scientific Analyst
  • Licensing / Portfolio Manager
  • Strategy Manager

For additional details and/or to request sample pages, please email at sales@rootsanalysis.com

The company had done another comprehensive research project on the ADC market in 2013. The details of this study can be found on the company's website.

About Roots Analysis

Roots Analysis is an industry leader in providing business research and competitive intelligence services. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. We specialize in researching areas which have lacked quality research, so far, and those that require a more focused approach to understanding the intricacies of affiliated technologies, or industry-specific details. If you’d like us to help you with your growing business needs, get in touch at  info@rootsanalysis.com 


  • We are your partners with no equity

  • We fit in your budget

  • We love what we do

  • Chance to prove ourselves

  • Best in class quality of work

  • Most trusted consulting partner in the industry